As shown in Fig. 7d, while 2DG enhanced the anti-tumor activity of both anti-PD-1 and anti-PD-L1 treatments, the effects were more pronounced with the anti-PD-L1 blockade. This evidence concerns the gene CD274 and neoplasm.